Fatigue and multiple sclerosis

Annales de Readaptation et de Medecine Physique

Volumn 49, Issue 6, 2006, Pages 355-360

  Bethoux F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Assessment; Fatigue; Multiple sclerosis; Rehabilitation

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BEE VENOM; CYCLOPHOSPHAMIDE; HERBACEOUS AGENT; INTERFERON; MITOXANTRONE; MODAFINIL; PEMOLINE; SEROTONIN UPTAKE INHIBITOR; VITAMIN;

AEROBIC EXERCISE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISTRESS SYNDROME; DRUG DEPENDENCE; ENERGY CONSERVATION; FATIGUE; HEADACHE; HUMAN; INFECTION; INSOMNIA; IRRITABILITY; LIVEDO RETICULARIS; LIVER TOXICITY; MENTAL DISEASE; MULTIPLE SCLEROSIS; NARCOLEPSY; NAUSEA; NERVOUSNESS; NIGHTMARE; PAIN; PARESTHESIA; QUALITY OF LIFE; RATING SCALE; RISK FACTOR; SEIZURE; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDER; SPASTICITY; SYMPTOMATOLOGY;

EID: 33745646040     PISSN: 01686054     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annrmp.2006.04.022     Document Type: Short Survey

References (38)

1. Agence nationale d'accréditation et d'évaluation en santé-Fédération française de neurologie. Conférence de Consensus sur la sclérose en plaques: texte des recommandations (2001) (22p)
2. Beenakker E.A.C., Oparina T.I., Hartgring A., Teelken A., Arutjunyan A.V., and De Keyser J. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 57 (2001) 892-894
3. Cohen R.A., and Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol. 46 6 (1989) 676-680
4. Cohen R., Marinucci L., Blight A., Katz M., Goodman A., and Cohen J. Responder analysis of walking speed applied to a trial of Fampridine in subjects with MS. Neurology 64 Suppl 1 (2005) A388
5. Cookfair D., Fischer J., Rudick R.A., and the MSCRG. Fatigue severity in low disability MS patients participating in a phase III clinical trial of of Avonex (IFN-1a) for relapsing multiple sclerosis. Neurology 48 supplement 2 (1997) A173
6. Di Fabio R., Soderberg J., Choi T., Hansen C., and Schapiro R. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch. Phys. Med. Rehabil. 79 (1998) 141-146
7. +-ATPase concentration and fiber type distribution after spinal cord injury. Muscle Nerve 29 1 (2004) 38-45
8. Edgley K., Sullivan M., and Dehoux E. A survey of multiple sclerosis: II Determinants of employment status. Can J Rehabil 4 (1991) 127-132
9. Fisk J.D., Pontefract A., Ritvo P.G., Archibald C.J., and Murray T.J. The impact of fatigue on patients with multiple sclerosis. Can. J. Neurol. Sci. 21 1 (1994) 9-14
10. Fisk J.D., and Doble S.E. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual. Life Res. 11 3 (2002) 263-272
11. Freal J.F., Kraft G.H., and Coryell J.K. Symptomatic fatigue in MS. Arch. Phys. Med. Rehabil. 65 (1984) 135-138
12. Freeman J., Langdon D., Hobart J., and Thompson A. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann. Neurol. 42 (1997) 236-244
13. Freeman J., Langdon D., Hobart J., and Thompson A. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over in the community?. Neurology 52 (1999) 50-56
14. Iriarte J., Katsamakis G., and de Castro P. The fatigue descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult. Scler. 5 (1999) 10-16
15. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14 (1991) 540-545
16. Kent-Braun J.A., Sharma K.R., Weiner M.W., and Miller R.G. Effects of exercise on muscle activation and metabolism in MS. Muscle Nerve 17 (1994) 1162-1169
17. Krupp L.B., Alvarez L.A., LaRocca N.G., and Scheinberg L.C. Fatigue in multiple sclerosis. Arch. Neurol. 45 (1988) 435-437
18. Krupp L.B., LaRocca N.G., Muir-Nash J., and Stenberg A.D. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 36 (1989) 1121-1123
19. Krupp L.B., LaRocca N.G., Muir J., and Steinberg A.D. Fatigue characteristics in systemic lupus erythematosus. J. Rheumatol. 17 (1990) 1450-1452
20. Krupp L.B., Coyle P.K., Doscher C., Miller A., Cross A.H., Jandorf L., et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 45 11 (1995) 1956-1961
21. Mathiowetz V.G., Finlayson M.L., Matuska K.M., Chen H.Y., and Luo P. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult. Scler. 11 5 (2005) 592-601
22. Mostert S., and Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult. Scler. 8 2 (2002) 161-168
23. MS Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: Evidence Based management strategies for fatigue in multiple sclerosis (1998), Paralyzed Veterans of America (33p)
24. Murray T.J. Amantadine therapy for fatigue in multiple sclerosis. Can. J. Neurol. Sci. 12 3 (1985) 251-254
25. Parmenter B.A., Denney D.R., and Lynch S.G. The cognitive performance of patients with multiple sclerosis during periods of high and low fatigue. Mult. Scler. 9 (2003) 111-118
26. Petajan J.H., Gappmaier E., White A.T., Spencer M.K., Mino L., and Hicks R.W. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann. Neurol. 39 (1996) 432-441
27. Petrilli S., Durufle A., Nicolas B., Robineau S., Kerdoncuff V., Le Tallec H., et al. Influence des variations de la température sur la symptomatologie clinique dans la sclérose en plaques: étude épidémiologique. Ann. Readapt. Med. Phys. 47 5 (2004) 204-208
28. Ponitchera-Mulcare J. Exercise and multiple sclerosis. Med. Sci. Sports Exerc. 25 (1993) 451-465
29. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., and Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J. Neurol. Neurosurg. Psychiatry 72 2 (2002) 179-183
30. Ritvo P.G., et al. Multiple sclerosis quality of life inventory: a user's manual (1997), National Multiple Sclerosis Society, New York
31. Roelcke U., Kappos L., Lechner-Scott J., Brunnschweiler H., Huber S., Ammann W., et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: an 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48 (1997) 1566-1571
32. Sharma K.R., Kent-Braun J., Mynhier M.A., Weiner M.W., and Miller R.G. Evidence of an abnormal intramuscular component of fatigue in MS. Muscle Nerve 18 (1995) 1403-1411
33. Sheean G.L., Murray N.M., Rothwell J.C., Miller D.H., and Thompson A.J. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 120 (1997) 299-315
34. Solari A., Filippini G., Gasco P., Colla L., Salmaggi A., La Mantia L., et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 52 (1999) 57-62
35. Stankoff B., Waubant E., Confavreux C., Edan G., Debouverie M., Rumbach L., et al., French Modafinil Study Group. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 64 7 (2005) 1139-1143
36. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can. J. Neurol. Sci. 14 3 (1987) 273-278
37. White A.T., Wilson T.E., Davis S.L., and Petajan J.H. Effects of precooling on physical performance in multiple sclerosis. Mult. Scler. 6 (2000) 176-180
38. Zifko U.A., Rupp M., Schwarz S., Zipko H.T., and Maida E.M. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J. Neurol. 249 8 (2002) 983-987